Teva Pharmaceutical Industries Limited (TEVA)
Pre-Market:
| Previous Close | 13.18 |
| Open | 13.17 |
| Bid | 0.00 x 3100 |
| Ask | 0.00 x 3200 |
| Day's Range | 12.75 - 13.21 |
| 52 Week Range | 7.09 - 14.47 |
| Volume | |
| Avg. Volume | 10,492,993 |
| Market Cap | 14.475B |
| Beta (5Y Monthly) | 1.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.50 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Nov 27, 2017 |
| 1y Target Est | 15.50 |
ZacksZacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
Teva, Dr. Reddy's and Viatris have been highlighted in this Industry Outlook article.
Zacks3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, TEVA and VTRS.
Business WireAlvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
REYKJAVIK, Iceland & PARSIPPANY, N.J., April 16, 2024--Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. Under
